FEDERAL COURT OF AUSTRALIA
Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd (No 3) [2025] FCA 1179
File number(s): NSD 698 of 2024 Judgment of: JACKMAN J Date of judgment: 24 September 2025 Catchwords: PATENTS – application for revocation of certain claims of patent on basis that claims are neither novel nor involve inventive step within meaning of s 18(1)(b) of the Patents Act 1990 (Cth) (Patents Act) when compared to prior art base – cross-claim for infringement of patent – where specification is a pour-on anthelmintic formulation for cattle involving a selected levamisole active ingredient and a macrocyclic lactone dissolved in a non-aqueous system that is stable – where prior art base existed before priority date – where expert witness relies on greater knowledge than common general knowledge (CGK) attributable to a person skilled in the art (PSA)
PATENTS – whether claims of patent lack inventive step – legal principles concerning prior art base, common general knowledge and obviousness considered – where expert witnesses required to undertake task of developing anthelmintic, using knowledge as at priority date – where applicant’s expert evidence does not reflect position of PSA – where comparison of other similar patents – inventive step found
PATENTS – whether claims of patent lack novelty – whether necessary to consider a notional set of claims, in valid form, which would be fairly based, as set out in Du Pont (defined in reasons) – where language of Patents Act does not require Court to determine hypothetical validity of notional claim – where notional claim requirement adds unnecessary complexity which was not intended by legislature – notional claim requirement is unnecessary – comparison of prior art document with patent in suit undertaken, claim by claim – each of contested claims held to be novel
HIGH COURT AND FEDERAL COURT – decision whether or not to follow previous judge’s decision should not be based on ‘judicial comity’ – where compelling reason to depart from previous judge
EVIDENCE – whether a Ferrcom inference (as defined in reasons) can apply to expert evidence – where difficulty determining whether there has been ‘fear’ of evidence being given or whether the significance of the evidence was simply not appreciated when the evidence in chief was prepared much earlier – where features of contemporary practice require expert reports to declare that all appropriate inquiries have been made and no matters of significance omitted – where no room left to tactically seek to avoid subject matter – Ferrcom inference superseded
Legislation: Patents Act 1990 (Cth) Cases cited: Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd [2024] FCA 1488
Aktiebolaget Hässle v Alphapharm Pty Ltd [2002] HCA 59; (2002) 212 CLR 411
Apple Inc v Samsung Electronics Co Ltd [2011] FCA 1164; (2011) 284 ALR 309
Aristocrat Technologies Australia Pty Ltd v Commissioner of Patents [2025] FCAFC 131
Aristocrat Technologies Australia Pty Ltd v Global Gaming Supplies Pty Ltd [2009] FCA 1495; (2009) 84 IPR 222
Keep reading for free
Create a free CaseChat account to read Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd (No... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2025] FCA 1179
- Decision Date
CaseChat Overview and Summary
The court found that the expert evidence should not be subject to a Ferrcom inference as contemporary practice concerning expert evidence does not allow for a party to tactically avoid certain subject matter. The court also held that the requirement to consider a notional set of claims for assessing novelty was unnecessary and added complexity that was not intended by the legislature. The court compared the prior art documents with the patent in question, claim by claim, and found each of the contested claims to be novel. The court determined that the patent claims involved an inventive step, finding that the applicant's expert evidence did not reflect the position of a person skilled in the art.
The court concluded that Abbey's challenge to the claims in the patent had only limited success, revoking three claims but upholding the rest. Virbac was granted declarations, injunctions, and an inquiry into pecuniary remedies. Abbey was given a four-week period before the injunctions took effect to allow for an orderly wind-down. The court set a timetable for the parties to file affidavits and written submissions on the question of costs.
Orders
Orders of the court
4. From 22 October 2025, each Cross-Respondent, whether by itself, its directors, officers, servants or agents, or otherwise be restrained, from infringing each of claims 1 to 10, 13, 15, 16 and 18 of the Patent, including by engaging in any of the following acts within Australia during the term of the Patent without the licence or authority of the Cross-Claimant:
(a) manufacturing in Australia, or importing into Australia, Levamox Duo;
(b) selling, supplying or otherwise disposing of Levamox Duo in Australia;
(c) offering to manufacture, sell, supply or otherwise dispose of Levamox Duo in Australia; and
(d) authorising, procuring, inducing or joining in a common design with any other person to engage in any of the acts referred to in sub-paragraphs (a) to (c) above.
5. By 22 October 2025, the Cross-Respondents destroy or deliver up to the Cross-Claimant on oath all Levamox Duo, together with all advertising, promotional and packaging material relating to such products, in the possession, custody, power or control of each Cross-Respondent in Australia.
6. Claims 19, 20 and 21 of the Patent be revoked pursuant to s 138(3) of the Patents Act 1990 (Cth).
7. There be an inquiry as to damages or an account of profits.
8. The Originating Application otherwise be dismissed.
9. The Respondent/Cross-Claimant file and serve any affidavits and written submissions in relation to costs by 17 October 2025.
10. The Applicant/Cross-Respondents file and serve any affidavits and written submissions in relation to costs by 31 October 2025.
11. The Respondent/Cross-Claimant file and serve any affidavits and written submissions in reply in relation to costs by 14 November 2025.
12. The matter be listed for case management in relation to the question of the assessment of pecuniary remedies on 31 October 2025 at 9.30 am.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
The matter came before the Federal Court of Australia following Abbey Laboratories Pty Ltd's application for the revocation of certain claims of a patent held by Virbac (Australia) Pty Ltd. Virbac cross-claimed for infringement of its patent by Abbey. The case involved extensive expert evidence and argument on the novelty and inventive step of the patent claims, as well as on the interpretation of the relevant provisions of the Patents Act 1990 (Cth). The court considered the prior art base, the common general knowledge of a person skilled in the art, and the specific task set for the experts in preparing their evidence. The decision also addressed the application of Ferrcom inferences to expert evidence and the requirements for notional claims in patent law.
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
In determining whether the claims of the patent lacked inventive step, the court examined the prior art base and the common general knowledge attributable to a person skilled in the art. It required the expert witnesses to undertake the task of developing an anthelmintic using their knowledge as at the priority date. The court found that the applicant’s expert evidence did not reflect the position of a person skilled in the art, and that there was an inventive step when comparing other similar patents. Thus, the court concluded that the claims did not lack inventive step.
Regarding the novelty of the claims, the court considered whether a notional set of claims, in valid form, which would be fairly based on the prior art, was necessary. The court found that the language of the Patents Act did not require the court to determine the hypothetical validity of a notional claim. It concluded that the notional claim requirement adds unnecessary complexity which was not intended by the legislature. By comparing the prior art document with the patent in suit, claim by claim, the court found each of the contested claims to be novel.
The court addressed whether it should follow a previous judge's decision based on 'judicial comity' or depart from it. The court determined that the decision should not be based on 'judicial comity' and that there was a compelling reason to depart from the previous decision.
In relation to the Ferrcom inference and its applicability to expert evidence, the court noted that contemporary practice in expert evidence, as evidenced by the Federal Court’s Expert Evidence Practice Note (GPN–EXPT), requires experts to declare that all appropriate inquiries have been made and no matters of significance have been omitted. The court concluded that such practice left no room for a party to tactically ensure that certain subject matter was avoided by an expert witness engaged by that party, particularly where that subject matter was dealt with by a competing expert witness. Thus, the court found that the Ferrcom inference was superseded.
Finally, the court interpreted the requirement for a notional set of claims in patent law, concluding that the language of the Patents Act did not necessitate the determination of the hypothetical validity of a notional claim and that the notional claim requirement adds unnecessary complexity which was not intended by the legislature. The court compared the prior art document with the patent in suit, claim by claim, and found each of the contested claims to be novel.